AI Terminal

MODULE: AI_ANALYST

Interactive Q&A, Risk Assessment, Summarization

MODULE: DATA_EXTRACT

Excel Export, XBRL Parsing, Table Digitization

MODULE: PEER_COMP

Sector Benchmarking, Sentiment Analysis

SYSTEM ACCESS LOCKED

Authenticate / Register Log In

029 Group SE

M&A Activity • Dec 1, 2005

4544_rns_2005-12-01_a6a1948b-a17d-47a0-8820-069dccc0ec4a.html

M&A Activity

Open in Viewer

Opens in native device viewer

News Details

Ad-hoc | 1 December 2005 19:03

Rhein Biotech N.V.: Statement re. Crucell’s plan to launch offer for Berna

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— The Board of Rhein Biotech NV took note of today’s announcement that Crucell NV plans to launch a take-over offer on Berna Biotech AG, the majority shareholder of Rhein Biotech NV. At this moment, Rhein Biotech NV is not involved in this proposed transaction and is not aware of any plans related thereto that may have a material effect on Rhein Biotech NV. Rhein Biotech N.V. Oude Maasstraat 47 6229 BC Maastricht Netherlands ISIN: NL0000230324 WKN: 919544 Listed: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart End of ad hoc announcement (c)DGAP 01.12.2005